Volver a Agenda
Session Chair(s)
Stella Stergiopoulos, MPH, MS
Director, Health Economic and Outcomes Research
EQRx, United States
Learning Objective : Identify and map a common and uniform nonclinical through early stage clinical process, to benchmark cycle time and duration data in order to inform management decision-making; Discuss nonclinical drug development costs.
Speaker(s)
Characterizing the Development Pathway from Preclinical through Early Clinical Drug Development
Stella Stergiopoulos, MPH, MS
EQRx, United States
Director, Health Economic and Outcomes Research
Translational Value of Early Target-based Safety Assessment and Associated Risk Mitigation
Laszlo A. Urban, DRSC, MD, PHD
Novartis Institutes for BioMedical Research, Inc., United States
Global Head, Preclinical Safety Profiling
Opportunities for Achieving Higher Levels of Efficiency in Preclinical Research
Simone Braggio, DRSC
Aptuit, Italy
Director, Drug Design and Discovery
¿Tiene una cuenta?